Compare Abeona Therapeutics Inc (ABEO) vs Matson Inc (MATX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Matson Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Matson Inc trades at $200.89 (market cap $6.01B). The key difference: Matson Inc is far larger — about 16.1× Abeona Therapeutics Inc's market cap, and Matson Inc pays a 0.77% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MATX | |
|---|---|---|
Market Cap | $373.32M | $6.01B |
Sector | Health | Technology |
52-Week High | $7.23 | $204.53 |
52-Week Low | $4.17 | $88.05 |
Enterprise Value | $228.22M | $6.61B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Matson (MATX) trades at $204.53, up 0.49% with strong technical momentum near resistance at $206. The stock shows robust fundamentals with consistent earnings beats, a 12.92% net margin, and shareholder-friendly actions including dividend increases and share buybacks. Recent news highlights the company's niche Pacific shipping advantages and operational efficiency gains.
Outlook remains positive given analyst consensus (64% buy ratings) and strong profitability metrics, though risks include shipping rate volatility and macroeconomic sensitivity. The current valuation at 15.17x P/E appears reasonable for a company with double-digit ROE and dividend growth, positioning MATX as a quality mid-cap transportation play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
